Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Journal of Neurology|September 3, 2014
NADPH oxidase (NOX2) activity is a modifier of survival in ALSGiuseppe Marrali, Federico Casale, Paolina Salamone, et al.
Annals of Neurology|February 1, 2025
Frequency and Early Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Longitudinal Population-Based StudyBarbara Iazzolino, Francesca Palumbo, Cristina Moglia, et al.
Neurobiology of Aging|May 11, 2012
Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosisYevgeniya Abramzon, Janel O Johnson, Sonja W Scholz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 21, 2021
A novel splice site FUS mutation in a familial ALS case: effects on protein expressionAntonio Canosa, Annarosa Lomartire, Giovanni De Marco, et al.
Neurology|October 27, 2020
Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 MutationBarbara Iazzolino, Laura Peotta, Jean Pierre Zucchetti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 10, 2019
Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohortLucia Corrado, Maura Brunetti, Alice Di Pierro, et al.
Neurology|October 27, 2012
Extensive genetics of ALS: a population-based study in ItalyAdriano Chiò, Andrea Calvo, Letizia Mazzini, et al.
Clinical Colorectal Cancer|September 10, 2011
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimenLorenzo Fornaro, Enrico Vasile, Gianluca Masi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 22, 2014
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patientsAngelina Cistaro, Marco Pagani, Anna Montuschi, et al.
Annals of Surgery|February 28, 2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastasesGianluca Masi, Fotios Loupakis, Luca Pollina, et al.
Pageof 8